BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 33687750)

  • 21. Total skeletal, psoas and rectus abdominis muscle mass as prognostic factors for patients with advanced hepatocellular carcinoma.
    Wu CH; Liang PC; Hsu CH; Chang FT; Shao YY; Ting-Fang Shih T
    J Formos Med Assoc; 2021 Jan; 120(1 Pt 2):559-566. PubMed ID: 32651043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.
    Hsieh MH; Kao TY; Hsieh TH; Kao CC; Peng CY; Lai HC; Chuang PH; Kao JT
    PLoS One; 2020; 15(12):e0244293. PubMed ID: 33382703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
    Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
    Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
    Trials; 2014 Dec; 15():474. PubMed ID: 25472660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spectrum of subclinical and overt hypothyroidism: effect on thyrotropin, prolactin, and thyroid reserve, and metabolic impact on peripheral target tissues.
    Staub JJ; Althaus BU; Engler H; Ryff AS; Trabucco P; Marquardt K; Burckhardt D; Girard J; Weintraub BD
    Am J Med; 1992 Jun; 92(6):631-42. PubMed ID: 1605145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Pinter M; Sieghart W; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Matejka J; Stauber R; Buder R; Grünberger B; Schöniger-Hekele M; Müller C; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2011 Oct; 34(8):949-59. PubMed ID: 21883324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A new prognostic score system of hepatocellular carcinoma following hepatectomy].
    Wang YK; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Li MX; Chen X; Wu XL; Mao R; Hu XH; Hu HJ; Liu JM; Cai JQ
    Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):903-909. PubMed ID: 29262506
    [No Abstract]   [Full Text] [Related]  

  • 28. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
    Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
    Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
    Abdel-Rahman O; Abdelwahab M; Shaker M; Abdelwahab S; Elbassiony M; Ellithy M
    J Egypt Natl Canc Inst; 2014 Mar; 26(1):9-13. PubMed ID: 24565677
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.
    Shao YY; Liu TH; Hsu C; Lu LC; Shen YC; Lin ZZ; Cheng AL; Hsu CH
    Liver Int; 2019 Nov; 39(11):2184-2189. PubMed ID: 31400295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma.
    Lyu N; Kong Y; Mu L; Lin Y; Li J; Liu Y; Zhang Z; Zheng L; Deng H; Li S; Xie Q; Guo R; Shi M; Xu L; Cai X; Wu P; Zhao M
    J Hepatol; 2018 Jul; 69(1):60-69. PubMed ID: 29471013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib.
    Zheng YB; Zhao W; Liu B; Lu LG; He X; Huang JW; Li Y; Hu BS
    Asian Pac J Cancer Prev; 2013; 14(9):5527-31. PubMed ID: 24175853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.
    Shao YY; Lin ZZ; Hsu C; Shen YC; Hsu CH; Cheng AL
    Cancer; 2010 Oct; 116(19):4590-6. PubMed ID: 20572033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Labenz C; Prenosil V; Koch S; Huber Y; Marquardt JU; Schattenberg JM; Galle PR; Weinmann A; Wörns MA
    Dig Dis; 2018; 36(1):78-88. PubMed ID: 28675895
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
    Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
    Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
    Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
    J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aggressive intrahepatic therapies for synchronous hepatocellular carcinoma with pulmonary metastasis.
    Hu Z; Huang P; Zhou Z; Li W; Xu J; Xu K; Wang J; Zhang H
    Clin Transl Oncol; 2018 Jun; 20(6):729-739. PubMed ID: 29110217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
    Lee IC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lin HC; Lee FY; Huang YH
    Medicine (Baltimore); 2015 Apr; 94(14):e688. PubMed ID: 25860213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association between esophagogastric varices in hepatocellular carcinoma and poor prognosis after transarterial chemoembolization: A propensity score matching analysis.
    Su CW; Fang KC; Lee RC; Liu CA; Chen PH; Lee PC; Kao WY; Huang YH; Huo TI; Hou MC; Lin HC; Wu JC
    J Formos Med Assoc; 2020 Feb; 119(2):610-620. PubMed ID: 31542334
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.